Cover Image

Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus

Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35-74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compar...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmitt, Volker H. (Author) , Prochaska, Jürgen (Author) , Föll, Annegret Susanne (Author) , Schulz, Andreas (Author) , Keller, Karsten (Author) , Hahad, Omar (Author) , Koeck, Thomas (Author) , Troebs, Sven-Oliver (Author) , Rapp, Steffen (Author) , Beutel, Manfred (Author) , Pfeiffer, Norbert (Author) , Strauch, Konstantin (Author) , Lackner, Karl J. (Author) , Muenzel, Thomas (Author) , Wild, Philipp S. (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: Scientific reports
Year: 2021, Volume: 11, Pages: 1-12
ISSN:2045-2322
DOI:10.1038/s41598-021-98227-x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41598-021-98227-x
Verlag, lizenzpflichtig, Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIArticle&SrcApp=WOS&KeyAID=10.1038%2Fs41598-021-98227-x&DestApp=DOI&SrcAppSID=E1PvrHy7KU93szkb7hP&SrcJTitle=SCIENTIFIC+REPORTS&DestDOIRegistrantName=Springer+Science+and+Business+Media+LLC
Get full text
Author Notes:Volker H. Schmitt, Juergen H. Prochaska, Annegret S. Foell, Andreas Schulz, Karsten Keller, Omar Hahad, Thomas Koeck, Sven-Oliver Troebs, Steffen Rapp, Manfred Beutel, Norbert Pfeiffer, Konstantin Strauch, Karl J. Lackner, Thomas Muenzel, Philipp S. Wild
Description
Summary:Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35-74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (beta - 0.36, 95% CI - 0.63/- 0.09; P = 0.008) and diastolic function (beta 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (beta - 0.34, 95% CI - 0.53/- 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (beta - 0.656, 95% CI - 1.07/- 0.24; P = 0.0021) and diastolic dysfunction (beta 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HRperSD) 1.60, 95% CI 1.39-1.85; P < 0.0001) and all-cause mortality (HRperSD 1.36, 95% CI 1.25-1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function.
Item Description:Gesehen am 02.12.2021
Physical Description:Online Resource
ISSN:2045-2322
DOI:10.1038/s41598-021-98227-x

Similar Items